DAB389IL-2 fusion toxin targeted to interleukin-2 receptors data

SRGN announced that four of 11 patients showed a partial response and one showed a complete response to its second-generation fusion toxin. The preliminary results in one of three groups of lymphoma patients in a dose-escalation, Phase I/II trial were reported at the Second International Symposium on Cutaneous T-Cell Lymphoma in Chicago. ...